Lilly diabetes pill recommended for EU approval
Eli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval in Europe, putting the drug on track to enter the region’s market this year.
Bloomberg News
Articles
Lilly CEO: Immigration, tax laws slow innovation
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
Bayh, Card to tour U.S. in Chamber campaign against regulations
Former Senator Evan Bayh and former White House Chief of Staff Andrew Card will tour the U.S. in a campaign by the Chamber of Commerce urging small businesses to fight regulations they say are stunting job growth.
Republic orders 80 Airbus jets for Frontier
Republic’s agreement to add the Airbus planes, which have a value of about $7 billion at list prices, comes as it pursues a $120 million restructuring plan for Frontier after buying the Denver-based airline out of bankruptcy in 2009.
Pilots OK cuts, allowing Republic to pursue restructuring plan
Frontier Airlines pilots overwhelmingly approved concessions that will allow parent Republic Airways Holdings Inc. to pursue a $120 million restructuring at the unprofitable unit. Indianapolis-based Republic bought Frontier out of bankruptcy in 2009.
Republic pins Frontier Airlines’ fate to pilot vote on savings
Republic Airways Holdings Inc. is counting on pilots approving concessions to kick-start a $120 million restructuring plan at its Frontier Airlines unit, 20 months after buying the carrier out of bankruptcy.
Lilly wins ruling in dispute with Amylin over diabetes drugs
Eli Lilly and Co. won a ruling in a lawsuit brought by Amylin Pharmaceuticals Inc., which wants to prevent Lilly from using the same people to sell Amylin’s diabetes drug and that of a competitor.
WellPoint paying almost $800M for CareMore
Indianapolis-based WellPoint Inc. agreed to acquire CareMore Health Group to expand Medicare coverage in California, Arizona and Nevada. The insurer paid almost $800 million, according to people familiar with the deal.
Drug industry outlook negative through 2012, Moody’s says
Earnings growth will continue to slow in 2011 for most of the industry’s biggest companies, analyst predicts.
Medco may seek acquisition with biggest contract imperiled
Medco Health Solutions Inc., which operates a $140 million automated pharmacy and distribution center in Whitestown, has lost $3.5 billion in contracts since March.
Roche wins as high court limits university patent rights
Monday's Supreme Court decision is a victory for companies that collaborate with universities in research. Indianapolis-based Eli Lilly and Co. was among the companies that supported Roche.
Health insurers lose push to ease rate review
U.S. insurers led by WellPoint Inc. and UnitedHealth Group Inc. failed to get federal regulators to change a rule in the 2010 health-care overhaul that triggers a review of any premium increases exceeding 10 percent.
Indiana Downs owner halts lawsuit amid bankruptcy
Cordish Cos., a real-estate developer trying to build a casino near Baltimore, must temporarily halt a defamation lawsuit against the chief executive officer of Shelbyville casino owner Indianapolis Downs LLC, a federal judge said Tuesday.
Growth in drug spending to slow as generics rise
The annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical firms like Eli Lilly and Co. are facing.
Notre Dame says no to ‘Made in China’ on Irish goods
Ten years after adopting its policy, Notre Dame remains the only major U.S. university that forbids license holders such as Adidas AG to put the school logo on any product from China.
Lilly rejected by Supreme Court in Gemzar patent case
The justices Monday left intact a federal appeals court decision invalidating a patent that would have protected Gemzar from generic competition in the U.S. until May 2013.
Lilly drug to detect Alzheimer’s criticized by consumer group
Eli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain, shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
Simon Property results improve as store rents climb
Simon Property Group Inc., the largest U.S. shopping-mall owner, said funds from operations rose 75 percent in the first quarter as retail sales climbed.
KAR Auction plans to refinance with $1.5B term loan
KAR Auction Services Inc., a provider of vehicle-auction services, is seeking to refinance existing debt with a $1.5 billion senior secured term loan and a $250 million senior secured revolving credit facility.
Zimmer, peer sued over arthritic-knee treatments
Genzyme Corp., the drugmaker bought by Sanofi-Aventis SA this month, sued Zimmer Holdings Inc. and Anika Therapeutics Inc. alleging the companies’ treatments for arthritic knee pain infringe a patent.